Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Kudlow pointed to strong retail sales and low unemployment as signs that the U.S. economy remained strong.Marketsread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
The Supreme Court could strike down the constitutionality of the Consumer Financial Protection Bureau, an agency Elizabeth Warren has likened to her child and which Justice...2020 Electionsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Cigna CEO David Cordani doesn't see the Trump administration's new proposal to cut Medicare pharmacy benefit rebates as a threat to its growth, as it embarks on integrating its newly acquired PBM firm Express Scripts.
"The proposed rebate rule will not have a meaningful impact on our growth or earnings trajectory," Cordani told analysts, on the company's fourth-quarter earnings call Friday, adding that its Medicare plans are already designed to pass through discounts to members.
"So, we don't see a major implication to that business portfolio. And … it does not apply to the commercial marketplace," he said. "We do see some opportunities in the proposed rule … to even further accelerate value based care programs with the pharmaceutical manufacturers."
Late Thursday, the Trump administration proposed ending the rebate system for Medicare and other government health plans, which officials argue provide a "perverse incentive" for pharmaceutical makers to set artificially high list prices on drugs.
The news sent shares of companies in the drug supply chain lower after hours, and the losses continued in early trading Friday.
Cigna's Express Scripts is the nation's largest pharmacy benefit manager, with more than 80 million members; its shares fell as much as 5 percent. Shares of rivals CVS Health fell nearly 2 percent and UnitedHealth Group was down just over 1 percent in early trade.
Cigna shares were also under pressure after the health insurer forecast earnings and revenues for the firm's first year as a combined firm that were below Wall Street estimates.
Cigna is now expecting 2019 adjusted profits of $16 to $16.50 per share, well below the analyst consensus estimate of $16.74 per share, according to average estimates compiled by Refinitiv IBES. The insurer says it expects full-year revenues in the range of $131.5 billion to $133.5 billion, compared to the analyst estimate of $133.6 billion.
Analysts say management is likely being conservative because of a number of competitive shifts in the PBM's business. Rival Anthem will be transitioning its members from Express Scripts to its own in-house pharmacy benefits unit earlier than expected, while Cigna will be transitioning away from its contract with UnitedHealth's PBM OptumRx.
"Cigna may be setting a conservative 2019 bar against which it has confidence it can execute a 'beat and raise' pattern over the course of this year," noted BMO Capital Market analyst Matt Borsch in a research report.
Cigna reported fourth-quarter adjusted profits of $2.46 per share, which were 4 cents above the Refinitiv analyst estimate, as it reined in medical costs. The results for the quarter included 11 days of earnings as a combined company.
—By Bertha Coombs. Follow her on Twitter: @coombscnbc